Refine by
Potential Ad Therapeutic Equipment Supplied In Germany
8 equipment items found
Manufactured by:PeptaNova GmbH based inSandhausen, GERMANY
Phebestin is a synthetic inhibitor specifically targeting alanyl-aminopeptidase, also known as aminopeptidase N (APN). It plays a significant role in modulating the proliferation and function of human peripheral T cells. This compound, characterized by its (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-L-valyl-L-phenylalanine structure, is soluble in water, methanol, and DMSO, offering versatile ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding to proteins, thereby modulating their ability to catalyze biochemical reactions. However, a lot of proteins are difficult targets for SMOLs, since ...
by:Reaction Biology Corp. based inMalvern, PENNSYLVANIA (USA)
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone methyltransferase domain and has been found to play a role in the regulation of Hox gene expression. Although the ASH1L SET domain has been shown in vitro to ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
PLX-R18 cells release a combination of therapeutic proteins in response to a damaged or poorly functioning hematopoietic system; this system creates the blood cells that protect us from infection, uncontrolled bleeding and anemia. PLX-R18 is currently in a Phase I clinical trial to treat incomplete hematopoietic recovery following Hematopoietic Cell Transplantation (HCT) and in development to ...
Manufactured by:Immatics N.V. based inTuebingen, GERMANY
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel biologics allows any T cell in the body to become activated and attack the tumor, regardless of the T cells’ intrinsic ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas ...
Manufactured by:Toleris Biotherapeutics GmbH based inWürzburg, GERMANY
AIM Bio has developed a platform of Autoimmunity Modifying Biologicals (AIM Biologicals) that uses soluble, near-physiological proteins to induce selective, antigen-specific immune tolerance. These proteins mimic a natural process observed in pregnancy that protects the embryo from the maternal immune system. By leveraging optimized soluble versions of the non-classical MHC Ib molecule HLA-G, AIM ...